Temgicoluril

Last updated
Temgicoluril
Mebicar.svg
Clinical data
Trade names Adaptol, Mebicar
Other namesAdaptol; Mebicar; Mebicarum; Mebikar; Tetramethylglycoluril; 1,3,4,6-Tetramethylglycoluril
ATC code
Legal status
Legal status
  • US:Unscheduled; not FDA approved
Pharmacokinetic data
Metabolism Gastrointestinal tract: 77–80%
Elimination half-life 3 hours [1]
Excretion Urine: 55–70%
Identifiers
  • 1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C8H14N4O2
Molar mass 198.226 g·mol−1
3D model (JSmol)
  • CN1C2C(N(C1=O)C)N(C(=O)N2C)C
  • InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3
  • Key:XIUUSFJTJXFNGH-UHFFFAOYSA-N

Temgicoluril (INN Tooltip International Nonproprietary Name), [2] also known as tetramethylglycoluril and sold under the brand names Adaptol and Mebicar, is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in Latvia and Russia. [3]

Contents

The chemical structure of temgicoluril is somewhat similar to uric acid and it doesn't interact with acids, alkali, oxidants and reducing agents. It seems to affect all major neurotransmitter systems. [4]

Temgicoluril has an effect on the structure of limbic–reticular activity, particularly on hypothalamus emotional zone, as well as on all several basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin, and adrenergic activity. It decreases brain norepinephrine levels and increases brain serotonin levels without modulating dopaminergic systems or cholinergic systems. [5]

Temgicoluril purportedly has anti-anxiety (anxiolytic) properties. [5] [6] [7] [8] [9] It is also used to aid smoking cessation. [3] In addition, temgicoluril may be useful in the treatment of ADHD symptoms. [10] In contrast with typical anxiolytic medications such as benzodiazepines, temgicoluril is non-habit forming, non-sedating, and does not impair motor function. [6] [3]

It can be prepared by condensation of N,N-dimethylurea with glyoxal. One publication described such a procedure. They combined N,N-dimethylurea and glyoxal with a catalytic amount of phosphoric acid anhydride in an aqueous solution at room temperature and after sufficient time temgicoluril was conveniently isolated by filtration. The filtrate can be re-used by adding more dimethylurea and glyoxal (no additional catalyst is needed) and obtaining respectable yields, although this requires a longer reaction time. [11]

As of 2021, temgicoluril has not been evaluated outside of Latvia and Russia.

Medical uses

Temgicoluril is used in Latvia and Russia, as a pharmaceutical drug to treat anxiety and to prevent or reduce anxiety, unrest, fear, internal emotional tension and irritability, reduce neuroses and neurotic disorders, heartburns of non-coronary heart disease origin. These effects are not accompanied with relaxation of muscle tone and impaired coordination of movement, suppression of mental and physical activity, so the drug can be used without interruption of work or school.

Temgicoluril does not have a direct effect on sleep, however, it enhances the effectiveness of sleep medicines and normalizes the course of disturbed sleep. Temgicoluril alleviates or eliminates the manifestations of nicotine dependence that occur after smoking cessation. Although temgicoluril does not cause mood swings or euphoria, habituation, nor addiction, withdrawal syndrome has been observed.[ contradictory ]

Side effects

Possible and rare side effects may include dizziness, hypotension, indigestion, allergic reactions (itchy skin) after high doses, hypothermia, fatigue. And lowered blood pressure and/or body temperature decreased by 1 to 1.5 °C. Blood pressure and body temperature return to normal after completion of treatment. [12]

See also

Related Research Articles

An anxiolytic is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain pathways facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT2.

<span class="mw-page-title-main">Tianeptine</span> Atypical antidepressant

Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.

<span class="mw-page-title-main">Piribedil</span> Drug used in the management of Parkinsons disease

Piribedil (trade names Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium and others) is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.

Oneiroid syndrome (OS) is a condition involving dream-like disturbances of one's consciousness by vivid scenic hallucinations, accompanied by catatonic symptoms (either catatonic stupor or excitement), delusions, or psychopathological experiences of a kaleidoscopic nature. The term is from Ancient Greek "ὄνειρος" (óneiros, meaning "dream") and "εἶδος" (eîdos, meaning "form, likeness"; literally dream-like / oneiric or oniric, sometimes called "nightmare-like"). It is a common complication of catatonic schizophrenia, although it can also be caused by other mental disorders. The dream-like experiences are vivid enough to seem real to the patient. OS is distinguished from delirium by the fact that the imaginative experiences of patients always have an internal projection. This syndrome is hardly mentioned in standard psychiatric textbooks, possibly because it is not listed in DSM.

<span class="mw-page-title-main">Mesocarb</span> Stimulant drug

Mesocarb is a drug that is currently being developed for Parkinson's disease.

Calcium pangamate is a mineral supplement. It is sometimes used as a synonym for pangamic acid.

<span class="mw-page-title-main">Periciazine</span> Typical antipsychotic medication

Periciazine (INN), also known as pericyazine (BAN) or propericiazine, is a drug that belongs to the phenothiazine class of typical antipsychotics.

<span class="mw-page-title-main">Bromantane</span> Stimulant drug

Bromantane, sold under the brand name Ladasten, is an atypical psychostimulant and anxiolytic drug of the adamantane family related to amantadine and memantine which is used in Russia in the treatment of neurasthenia. Although the effects of the bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and it is distinct in its properties relative to typical psychostimulants such as amphetamine. Because of its unique aspects, bromantane has sometimes been described instead as an actoprotector.

<span class="mw-page-title-main">Fabomotizole</span> Anxiolytic drug

Fabomotizole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.

<span class="mw-page-title-main">Selank</span> Chemical compound

Selank is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of human tuftsin.

<span class="mw-page-title-main">Pipofezine</span> Chemical compound

Pipofezine, sold under the brand name Azafen or Azaphen, is a tricyclic antidepressant approved in Russia for the treatment of depression. It was introduced in the late 1960s and is still used today.

<span class="mw-page-title-main">Echinopsidine</span> Chemical compound

Echinopsidine (Adepren) is an antidepressant that was under development in Bulgaria for the treatment of depression. It increases serotonin, norepinephrine, and dopamine levels in the brain and is believed to act as a monoamine oxidase inhibitor (MAOI). Echinopsidine is found naturally in Echinops echinatus along with the related alkaloids echinopsine and echinozolinone.

<span class="mw-page-title-main">Emoxypine</span> Chemical compound

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin, a succinate salt, is chemical compound which is claimed by its manufacturer, the Russian company Pharmasoft Pharmaceuticals, to have antioxidant and actoprotector properties.

<span class="mw-page-title-main">Benzobarbital</span> Chemical compound

Benzobarbital (Benzonal) is a barbiturate derivative. It has anticonvulsant effects and has been used for the treatment of epilepsy.

<span class="mw-page-title-main">Semax</span> Chemical compound

Semax is a drug which is used mostly in Russia for a broad range of conditions but predominantly for its purported nootropic, neuroprotective, and neurorestorative properties. Semax has not been evaluated, approved for use, or marketed in most other countries. It is prescribed in eastern Europe and Russia for brain trauma.

<span class="mw-page-title-main">Ipidacrine</span> Chemical compound

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound is a modification of the older drug tacrine (Cognex).

Actoprotectors or synthetic adaptogens are compounds that enhance an organism's resilience to physical stress without increasing heat output. Actoprotectors are distinct from other performance-enhancing substances in that they increase physical and psychological resilience via non-exhaustive action. The term "actoprotector" is used to describe synthetic and isolated compounds possessing adaptogenic properties. By contrast, the term "adaptogen" is most often use to describe a natural herb as a whole, which can contain hundreds if not thousands of biologically active components.

Prospekta is a nootropic drug reported to act on the S100 proteins. It was developed by the company Materia Medica and approved in Russia for the treatment of ADHD in 2022. It was also studied for vascular dementia.

References

  1. ↑ US 20110070305,Schwarz J, Weisspapir M,"Sustained release pharmaceutical composition containing mebicar",published 2011-03-24, assigned to Alpharx Inc.
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (3). 2020.
  3. 1 2 3 "Adaptol product summary". JSC Olainfarm. Latvia. Archived from the original on 2013-10-13. Retrieved 2013-05-29.
  4. ↑ "Clinical Overview ADAPTOL" (PDF). JSC Olainfarm. Latvia. Archived (PDF) from the original on 8 September 2021.
  5. 1 2 Val'dman AV, Zaikonnikova IV, Kozlovskaia MM, Zimakova IE (May 1980). "[Characteristics of the psychotropic spectrum of action of mebicar]". Biulleten' Eksperimental'noi Biologii I Meditsiny. 89 (5): 568–570. PMID   6104993.
  6. 1 2 Val'dman AV, Zaikonnikova IV, Kozlovskaya MM, Zimakova IE (1980). "A study of the spectrum of psychotropic action of mebicar". Bulletin of Experimental Biology and Medicine. 89 (5): 621–624. doi:10.1007/BF00835799. S2CID   11343572.
  7. ↑ Mkrtchian VR, Kozhokova LZ (2012). "[Adaptol--verges of possible]". Likars'ka Sprava (5): 125–133. PMID   23534281.
  8. ↑ Chutko LS, Rozhkova AV, Sidorenko VA, Surushkina SI, Tursunova KB (2012). "[Generalized anxiety disorder: psychosomatic aspects and treatment approaches]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 112 (1): 40–44. PMID   22678674.
  9. ↑ Chutko LS, Surushkina SI, Nikishena IS, Iakovenko EA, Anisimova TI, Kuzovenkova MP (2010). "[Asthenic disorders in children]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 110 (11 Pt 1): 26–29. PMID   21183919.
  10. ↑ Chutko LS, Surushkina SI, Nikishena IS, Iakovenko EA, Anisimova TI, Sergeev AV (2009). "[Adaptol in the treatment of ADHD]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 109 (8): 45–48. PMID   19738569.
  11. ↑ Micheletti G, Delpivo C, Baccolini G (2013-06-01). "A green synthesis of glycoluril derivatives in aqueous solution with recycle of the waste". Green Chemistry Letters and Reviews. 6 (2): 135–139. Bibcode:2013GCLR....6..135M. doi: 10.1080/17518253.2012.718803 . ISSN   1751-8253. S2CID   96318579.
  12. ↑ "Adaptol (Mebicarum) - Summary of product characteristics". State Agency of Medicines of Latvia (in Latvian). Archived from the original on 7 August 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.